Nasdaq auph.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its business performance. Preliminary unaudited net revenue for the three months and full year ...AUPH Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is $14.20 with a high forecast of $15.00 and a low forecast of $13.00. The average price target represents a 71.29% change from the last price of $8.29.AUPH Latest Pre Market Trades. Select time range to see more trades: Last 100 Trades. ...Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...

AUPH Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is $14.20 with a high forecast of $15.00 and a low forecast of $13.00. The average price target represents a 71.29% change from the last price of $8.29.

To wit, the Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) share price is 78% higher than it was a year ago, much better than the market return of around 12% (not …AUPH | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Nov 20, 2023 · Nov. 20, 2023, 12:38 PM. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are trading higher, adding to gains of more than 17% over the last week. The stock has been trending higher since the ... Jul 18, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical needs. In 2021, it introduced Lupkynis ... VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on ...The company has $337.90 million in cash and $93.21 million in debt, giving a net cash position of $244.69 million or $1.70 per share. Cash & Cash Equivalents.

About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.

Aurinia Pharmaceuticals (NASDAQ: AUPH), in its third-quarter earnings call for 2023, reported a significant increase in net product revenue and ongoing expansion efforts, while also revealing that ...

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors (“the Board”) has appointed Dr ...AUPH Latest After Hours Trades. Select time range to see more trades: Last 100 Trades. After Hours Time (ET) After Hours Price. After Hours Share Volume. 19:59:23. $9.37. 100. Aurinia Pharmaceuticals (NASDAQ:AUPH) has been subject to buyout speculations for well over a year now. It was as early as May 2021, when The Times mentioned AstraZeneca ( AZN ) or GSK ( GSK ) are ...H.C. Wainwright analyst Ed Arce maintained a Buy rating on Aurinia Pharmaceuticals (NASDAQ: AUPH) on Friday, setting a price target of $35, which is approximately 142.38% above the present share ...Back to AUPH Overview. Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or ... Jul 18, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical needs. In 2021, it introduced Lupkynis ... The latest price target for Aurinia Pharmaceuticals ( NASDAQ: AUPH) was reported by HC Wainwright & Co. on Friday, September 22, 2023. The analyst firm set a price target for 15.00 expecting AUPH ...

To wit, the Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) share price is 78% higher than it was a year ago, much better than the market return of around 12% (not including dividends) in the same ...The public float for AUPH is 130.54M, and at present, short sellers hold a 13.23% of that float. The average trading volume of AUPH on November 20, 2023 was 1.70M shares. AUPH) stock’s latest price update. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)’s stock price has increased by 3.08 compared to its previous closing price of 8.60.Nov 29, 2023 · 2 analysts have issued twelve-month price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price targets range from $13.00 to $15.00. On average, they expect the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 62.8% from the stock's current price. View analysts price targets for AUPH or ... Aurinia Pharmaceuticals (NASDAQ:AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical needs. In 2021, it introduced Lupkynis ...AUPH Stock Overview. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. About the company. AUPH fundamental analysis.Aurinia Pharmaceuticals (AUPH) closed the last trading session at $9.80, gaining 0.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for third ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)Last month, AUPH's second largest shareholder, MKT Capital, which holds 4.2% of the stock, wrote a scathing letter to shareholders, calling to withdraw support for CEO Peter Greenleaf, board ...

Nov 29, 2023 · AUPH | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Cramer would be careful about Aurinia Pharmaceuticals Ord Shs (NASDAQ:AUPH). Sorrento Therapeutics Inc (NASDAQ:SRNE) is overvalued, said Cramer. He is a seller.Aug 31, 2023 · Fintel reports that on September 22, 2023, HC Wainwright & Co. reiterated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy recommendation. Analyst Price Forecast Suggests 72.67% Upside ... AUPH closed Tuesday's trading at $16.05, up 4.09%. ... views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.Aurinia Pharmaceuticals (NASDAQ:AUPH) recently released its Q4, 2017 results, as well as, provided an update on its pipeline.The company is continuing to progress well with its Phase III AURORA ...Fintel reports that on July 6, 2023, Cantor Fitzgerald reiterated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Overweight recommendation. Analyst Price Forecast Suggests 64.02% UpsideAUPH closed Tuesday's trading at $16.05, up 4.09%. ... views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.Aurinia Pharmaceuticals (NASDAQ: AUPH) will report its Q2 2021 earnings after the closing bell today and investors will want to pay attention to sales and any color management provides on its ...

Jun 16, 2023 · Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a good speculative biotech play to look into. That's because it already has received FDA approval of LUPKYNIS™ as an oral treatment for adult ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that leading independent proxy advisor Institutional Shareholder Services (“ISS”) has recommended that Aurinia shareholders vote FOR the re-election of all eight incumbent directors to the Board of Directors (the “Board”) at the Company’s 2023 …

Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...Earnings vs Market: AUPH is forecast to become profitable over the next 3 years, which is considered above average market growth. High Growth Earnings: AUPH …Analyst's Opinion · Consensus Rating. Aurinia Pharmaceuticals has received a consensus rating of Buy. · Price Target Upside/Downside. According to analysts' ...In trading on Thursday, shares of Aurinia Pharmaceuticals Inc (Symbol: AUPH) crossed above their 200 day moving average of $8.57, changing hands as high as $8.92 per share. Aurinia Pharmaceuticals ...About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Swiss National Bank raised its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 7.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).The firm owned 279,300 shares of the biotechnology company’s stock after acquiring an …June 30, 2023 — 02:07 pm EDT. Below is Validea's guru fundamental report for AURINIA PHARMACEUTICALS INC ( AUPH). Of the 22 guru strategies we follow, AUPH rates highest using our Value Investor ...Track Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Jan 12, 2023 · In trading on Thursday, shares of Aurinia Pharmaceuticals Inc (Symbol: AUPH) crossed above their 200 day moving average of $8.57, changing hands as high as $8.92 per share. Aurinia Pharmaceuticals ... Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript November 2, 2023 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.17.AUPH Inverse H&S Price has broken out of a down channel I see this breaking down slightly back into the channel, forming a right shoulder along the yellow horizontal and then continuing to pursue the reversal above the channel Lets see what happens on this Weekly chart Bars pattern in green shows my idea Price has broken out of a down channel I see this breaking down slightly back into the ...The average twelve-month price prediction for Aurinia Pharmaceuticals is $14.00 with a high price target of $15.00 and a low price target of $13.00. Learn more on AUPH's analyst rating history. Do Wall Street analysts like Aurinia Pharmaceuticals more than its competitors?Instagram:https://instagram. trading gold futuresforex volume indicatorsbest ev stockswhat is the best penny stock to buy Aurinia Pharmaceuticals (NASDAQ: AUPH) reversed an earlier decline and is now up 3.4% after a report indicated Biogen (NASDAQ: BIIB) could potentially look to target the company. Aurinia ( AUPH ... diamond stockjepq holdings Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest ...Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. todays market movers Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is certainly one of the US-listed biotech stocks with significant upside potential as this Canadian biotechnology company, having bolstered its patent ...Aurinia AUPH announced that it has acquired two new pipeline candidates, which will target rare autoimmune and kidney-related diseases. Both the candidates, renamed as AUR200 and AUR300 following ...Avid Bioservices Inc (NASDAQ:CDMO) has a beta value of 1.52 and has seen 0.52 million shares traded in the recent trading session. The company, currently valued at $305.42M, closed the recent trade at $4.84 per share which meant it lost -$0.15 on the day or -3.11% during that session. ... (NASDAQ:AUPH) has a beta value of 1.39 and has …